Printer Friendly

Amneal Biosciences unveils generic triamcinolone acetonide injectable suspension in the market.

M2 PHARMA-December 13, 2017-Amneal Biosciences unveils generic triamcinolone acetonide injectable suspension in the market

(C)2017 M2 COMMUNICATIONS

Pharmaceuticals company Amneal Biosciences disclosed on Tuesday the approval and availability of its Triamcinolone Acetonide Injectable Suspension, USP in 40 mg/ml dosage strength directly and through wholesalers and distributors.

According to the company, its triamcinolone acetonide will be sold in 1 ml single-dose vials as well as in 5 ml and 10 ml multiple dose vials.

The company added the triamcinolone acetonide injectable suspension is the only AP-rated generic equivalent to KenalogR-40 injection available in the market.

Annually, the US sales of Kenalog-40 injection were USD146m, according to October 2017 IQVIA market data, concluded the company.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Dec 13, 2017
Words:126
Previous Article:Allergan passes US FDA's clearance for the CoolSculpting treatment for the double chin.
Next Article:GSK awarded US FDA approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA).
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters